Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2026-05-17 @ 4:13 PM
Study NCT ID:
NCT00394251
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2006-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor:
Celgene
Organization: